

**Position statement on photodynamic therapy (PDT) for management of chronic serous chorionic retinopathy (CSCR)**

The Derbyshire-wide Clinical Policies Advisory Group (CPAG) have reviewed the most up to date evidence regarding photodynamic therapy (PDT) in management of chronic serous chorionic retinopathy.

On the basis that the studies were: -

- Often small scale (and were not sufficiently powered to draw accurate conclusions)
- Frequently lacked a control arm (making the true impact of PDT difficult to establish)
- Focussed on changes in eye anatomy, rather than impact on patient's vision and/or changes in vision were not statistically significant,

it is the decision of CPAG that PDT should not be routinely commissioned as an intervention for management of CSCR.

Where the clinician feels that PDT should be considered by exceptionality for a patient, then this should be outlined using an Individual Funding Request (IFR). A link to the IFR application form and IFR policy may be found here: -

<http://www.derbyshiremedicinesmanagement.nhs.uk/clinical-policies-home>

## References:

1. **Interventions for central serous chorioretinopathy: a network meta-analysis.**  
Salehi Mahsa The Cochrane database of systematic reviews 2015;(12):CD011841-.
2. **Photodynamic therapy for central serous chorioretinopathy.**  
Erikotola O. C Eye (London, England) 2014;28(8):944-957.
3. **System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy.**  
Ma Jinlan Acta ophthalmologica 2014;92(8):e594-.
4. **Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.**  
Vasconcelos Helena Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2013;251(7):1697-1705.
5. **A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.**  
Lai Frank H. P American journal of ophthalmology 2016;170:91-99
6. **Central serous chorioretinopathy: what we have learnt so far.**  
[Wong KH<sup>1</sup>](#), [Lau KP<sup>1</sup>](#), [Chhablani J<sup>2</sup>](#), [Tao Y<sup>3</sup>](#), [Li Q<sup>1</sup>](#), [Wong IY<sup>1</sup>](#). Acta Ophthalmol. 2016 Jun;94(4):321-5. doi: 10.1111/aos.12779
7. **Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).**  
Lai TY, Wong RL, Chan WM. Trans Am Ophthalmol Soc. 2015;113:T8
8. **Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review.**  
Chung YR, Seo EJ, Lew HM, Lee KH.
9. **Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.**  
Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H. Ophthalmology. 2014 Feb;121(2):558-65.

### Evidence review March 2019

Doyle J, Gupta B and Tahir I. Long term outcomes for patients treated with half-fluence photodynamic therapy for chronic serious chorioretinopathy: a case series. *Int J Ophthalmol* **2018**;11(2) 333 – 6.

Ladas ID, Adreanos KD, Ladas D, Moschos MM, Rotsos T, Kotsolis A. Three-year results of fluorescein angiography- guided standard photodynamic therapy with multiple spots for central serous chorioretinopathy. Doi accessed (abstract) on Thursday 7<sup>th</sup> March at <https://doi.org/10.1016/j.oret.2017.11.008>

Ruiz-del-Tiempo MP, Calvo P, Ferraras A, Lecinena J, Pablo L, Moreno-Ruiz O. Anatomical retinal changes after photodynamic therapy in chronic central serous chorioretinopathy. *J Ophthalmol* **2018** – doi accessed via <https://doi.org/10.1155/2018/2081874> on 7th March 2019.

**Date: March 2019**

**Review Date: February 2022**